24 mg/ml (2.4%), 5 ml ampoule, human medicine
Assessed clinical scopeDog · Monitored IV rescue treatment of acute, clinically important bronchospasm when inhaled beta2-agonist treatment is unavailable, inadequate or cannot be delivered; not routine first-line or chronic-airway treatment. · Intravenous
Care settingEmergency or hospital care with venous access, controlled slow infusion, ECG, blood-pressure and electrolyte monitoring and access to serum-theophylline measurement when prior exposure or repeated dosing makes it relevant
vetman score
Not rateable
No numerical score assigned
Evidence confidence: Low
Georgia: Suspended · № რ-031590, რ-031592, რ-039831 · Verified on 15 Oct 2026
Off-label use
Not rateable
This 5 ml catalogue row does not identify one exact medicinal product. It has no manufacturer or exact public label, while its Georgian market record combines three suspended authorisations under Euphyllin/Euphylline names and different validity dates. The concentration and pack alone cannot establish which composition, dossier, holder and safety information belong to the ampoule, so a numerical product rating would be misleading.
Aminophylline itself has a narrow, evidence-supported rescue role in monitored acute bronchospasm, but that ingredient-level evidence cannot identify or validate this unresolved 5 ml product. Confirm the manufacturer, authorisation number and exact current label before use; do not transfer the Biopolus or another 24–25 mg/ml product score to it.
Important safety and use flags
- Administer intravenously only as a controlled slow injection or infusion; never give a rapid bolus. A canine PK comparison produced a substantially lower immediate theophylline concentration with a 15-minute infusion than with a 30-second bolus.
- Aminophylline has a narrow therapeutic index. Before a loading dose, establish recent oral or injectable theophylline/aminophylline exposure whenever possible; monitor ECG, perfusion, blood pressure, electrolytes and clinical toxicity, and measure serum theophylline when prior exposure, repeated dosing or impaired clearance makes accumulation plausible.
- Avoid or use only after a compelling benefit-risk decision in active tachyarrhythmia, uncontrolled seizure disorder, active peptic ulceration or known hypersensitivity to theophyllines/ethylenediamine. Fever, shock, heart failure, hepatic disease and severe systemic illness can reduce clearance and require extra caution.
- Do not combine with another xanthine preparation unless total exposure and serum concentration are deliberately managed. Concurrent aminophylline plus theophylline from another product or route can produce serious additive toxicity.
- Fluoroquinolones, macrolides, cimetidine, propranolol and several other inhibitors can raise theophylline exposure; phenobarbital and other enzyme inducers can lower it. Review the full medication list, avoid high-risk combinations when possible and use serum monitoring/dose adjustment when unavoidable.
- Beta2 agonists, epinephrine and other sympathomimetics may add tachyarrhythmia and hypokalaemia risk. They may still be clinically indicated in an emergency, but combine only with ECG, electrolyte and haemodynamic monitoring rather than assuming bronchodilator effects are simply additive.
- Aminophylline solutions are alkaline and have important admixture incompatibilities. Do not mix or use a Y-site with another medicine until compatibility has been verified for the exact concentrations and diluent from a current hospital source.
- This is a rescue bronchodilator, not treatment of airway inflammation, anaphylactic shock, infection, pulmonary oedema or another cause of respiratory distress. Provide oxygen and cause-directed treatment; inhaled beta2 agonists are generally preferred when they can be delivered effectively.
- Use lean/appropriate body weight, verify that the vial strength is expressed as aminophylline rather than theophylline equivalent, and calculate both milligrams and millilitres independently. Stop or slow administration and reassess vomiting, marked agitation/tremor, hypotension, tachyarrhythmia or seizure activity.
- Safety of this exact human presentation in pregnant or lactating bitches/queens, neonates and breeding animals is not established. Use only when the monitored rescue benefit clearly outweighs the uncertainty; verify the exact product label, excipients, storage and single-use/discard instructions before administration.
Assessment sources+
